Dechert Advises Royalty Pharma on Sale of Promacta Royalties
March 31, 2019
Dechert advised Royalty Pharma on its sale of Ligand Pharmaceutical’s Promacta®-related intellectual property rights licensed to Novartis. The US$827 million transaction includes the royalty stream on worldwide net sales of Promacta®.
Promacta® (eltrombopag), known as Revolade® outside of the United States, is marketed worldwide by Novartis. Promacta® is expected to reach blockbuster status.
The Dechert team, which performed IP due diligence on the transaction, was led by intellectual property partner Carl Morales, Ph.D., and included IP associates Joseph W. Arico, Ph.D., and Blaine M. Hackman, Ph.D.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
